ViroMed Co Ltd (084990):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ViroMed Co Ltd (084990) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8016
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ViroMed Co Ltd (ViroMed), formerly ViroMedica Pacific Inc is a biotechnology company that discovers and develops biopharmaceuticals and phytotherapeutics for human diseases. The company provides therapeutic drugs such as therapeutic angiogenesis for cardiovascular diseases, therapeutic cancer vaccine and protein based therapeutic thrombocytopenia. Its pipeline products include VM501, VM202 and VM206. ViroMed’s therapeutic drugs target diseases such as thrombocytopenia, breast cancer, ovarian cancer, critical limb ischemia, painful diabetic peripheral neuropathy, angina pectoris, ischemic heart failure and amyotrophic lateral sclerosis, among others. The company also develops botanical and nutraceutical products. It operates in South Korea, China and the US. ViroMed is headquartered in Seoul, South Korea.

ViroMed Co Ltd (084990) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ViroMed Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
ViroMed Enters into Agreement with Reyon Pharmaceutical 10
Licensing Agreements 11
Bluebird bio Enters Into Licensing Agreement With ViroMed 11
Viromed Enters Into Licensing Agreement With Reyon Pharma For Hepatitis B Vaccine 12
Equity Offering 13
ViroMed to Raise USD159.8 Million in Rights Offering of Shares 13
ViroMed to Raise USD12.8 Million in Private Placement of Shares 14
ViroMed Announces Private Placement Of Shares For US$10 Million 15
Acquisition 16
Reyon Pharma Sells its Stake in ViroMed for USD108 Million 16
ViroMed Co Ltd – Key Competitors 17
ViroMed Co Ltd – Key Employees 18
ViroMed Co Ltd – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Product News 20
11/09/2017: ViroMed Builds Team of Experts to Complete New Global Drug Development 20
02/09/2017: VM BioPharma Announces Publication of Phase 1/2 Clinical Data of Novel Gene Therapy VM202 in Amyotrophic Lateral Sclerosis (ALS) 21
Product Approvals 22
Oct 30, 2017: VM BioPharma Announces Generic Name “donaperminogene seltoplasmid” for Investigational Novel Gene Therapy, VM202 22
Clinical Trials 23
Sep 25, 2017: ViroMed, Gene Therapy Powerhouse on Global Stage 23
Aug 03, 2017: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate VM202 for Non-Healing Diabetic Foot Ulcers 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ViroMed Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ViroMed Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ViroMed Enters into Agreement with Reyon Pharmaceutical 10
Bluebird bio Enters Into Licensing Agreement With ViroMed 11
Viromed Enters Into Licensing Agreement With Reyon Pharma For Hepatitis B Vaccine 12
ViroMed to Raise USD159.8 Million in Rights Offering of Shares 13
ViroMed to Raise USD12.8 Million in Private Placement of Shares 14
ViroMed Announces Private Placement Of Shares For US$10 Million 15
Reyon Pharma Sells its Stake in ViroMed for USD108 Million 16
ViroMed Co Ltd, Key Competitors 17
ViroMed Co Ltd, Key Employees 18

List of Figures
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[ViroMed Co Ltd (084990):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cohort Plc
    Cohort Plc - Strategy, SWOT and Corporate Finance Report Summary Cohort Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • El Pollo Loco Holdings, Inc.:企業の戦略・SWOT・財務情報
    El Pollo Loco Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary El Pollo Loco Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Lee Enterprises, Incorporated:企業の戦略・SWOT・財務情報
    Lee Enterprises, Incorporated - Strategy, SWOT and Corporate Finance Report Summary Lee Enterprises, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Noble Energy Inc (NBL)-石油・ガス分野:企業M&A・提携分析
    Summary Noble Energy, Inc. (Noble Energy) is an independent energy company that explores for and produces crude oil, natural gas and natural gas liquids (NGLs). The company’s portfolio includes both US unconventional and global offshore conventional assets in various countries. Noble Energy has oper …
  • Acuity Brands Inc (AYI):企業の財務・戦略的SWOT分析
    Acuity Brands Inc (AYI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • SomaLogic Inc:企業の製品パイプライン分析
    Summary SomaLogic Inc (SomaLogic) is a life science company that discovers, develops and commercializes life science research tools and clinical diagnostic products. The company’s products include SOMAscan assay and SOMAmer reagents. Its SOMAscan reagents is a proteomic platform that combines the pr …
  • Plant Bioscience Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Plant Bioscience Ltd (PBL) is a technology management company that offers services in plant, food and microbial science. The company provides intellectual property management, patent advisory, licensing and technology transfer services. It offers patient consultation and management services, …
  • Bangkok Bank Public Co Ltd:企業の戦略・SWOT・財務情報
    Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • A. Schulman Inc (SHLM):企業の財務・戦略的SWOT分析
    A. Schulman Inc (SHLM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Noxilizer Inc-医療機器分野:企業M&A・提携分析
    Summary Noxilizer Inc (Noxilizer) is a medical device company that manufactures sterilization equipment. The company’s products include industrial nitrogen dioxide sterilizer and biodecontamination systems. Its services comprise installation, contract sterilization services, and maintenance services …
  • 01 Communique (ONE):企業の財務・戦略的SWOT分析
    Summary 01 Communique (Communique) is a technology company that develops and delivers integrated communication software and services. The company's products include I'm InTouch meeting, I'm InTouch, I'm OnCall and Communicate!. Communique I'm InTouch provides a secure and easy to use PC remote acces …
  • Qatar Petroleum:企業の戦略的SWOT分析
    Qatar Petroleum - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Canbriam Energy Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Canbriam Energy Inc (Canbriam) is an oil and gas exploration company that offers finding and developing liquids rich natural gas resources. The company develops liquids rich natural gas resources in the Western Canadian Sedimentary Basin. It owns and operates oil and gas producing properties …
  • Aarhus University-製薬・医療分野:企業M&A・提携分析
    Summary Aarhus University (Aarhus) is a university that undertakes activities related to research, talent development, knowledge exchange and education. The university offers bachelor’s degree programmes, master’s degree programmes and PhD programmes in various disciplines. Its areas of academic int …
  • NiSource Inc (NI):石油・ガス:M&Aディール及び事業提携情報
    Summary NiSource Inc (NiSource) is a regulated energy utility. The company distributes natural gas; and generates, transmits and distributes electricity. It produces electricity from coal, gas and hydro sources. NiSource operates electricity transmission systems and natural gas transmission pipeline …
  • Skyworth Digital Holdings Limited:企業の戦略・SWOT・財務分析
    Skyworth Digital Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Skyworth Digital Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Maruho Co Ltd:企業の戦略的SWOT分析
    Maruho Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Petron Corp (PCOR):石油・ガス:M&Aディール及び事業提携情報
    Summary Petron Corp (Petron), a subsidiary of San Miguel Corporation, is a downstream energy company. It refines and markets an array of petroleum products including gasoline, liquefied petroleum gas, diesel, jet fuel, kerosene, industrial fuel oil, solvents, asphalts; and petrochemical feedstocks s …
  • Abaxis Inc:企業の戦略的SWOT分析
    Abaxis Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • University of Leicester-製薬・医療分野:企業M&A・提携分析
    Summary University of Leicester (UOL) is an educational service provider that offers undergraduate, postgraduate, distance learning and part-time programs. The university offers educational and research services in various disciplines such as mathematics, biochemistry, medicine, astrophysics, geneti …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆